Trial Profile
An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Registrational
- Acronyms Oriental
- Sponsors AstraZeneca
- 21 Jul 2023 Status changed from active, no longer recruiting to completed.
- 14 Mar 2023 Planned End Date changed from 30 Dec 2022 to 28 Mar 2023.
- 14 Mar 2023 Planned primary completion date changed from 30 Dec 2022 to 28 Mar 2023.